Immunocore

Immunocore

Primary Menu

  • About us
    • Management Team
    • Board of Directors
    • Partners
  • Our science
    • Pipeline
    • Publications
    • Scientific Advisory Board
  • Our therapy areas
    • Oncology
    • Infectious Diseases
    • Autoimmune and Inflammation Diseases
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us

Primary Menu

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us
  1. Home
  2. /
  3. News

News

  • 26 October 2018

    Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA
  • 5 September 2018

    Immunocore strengthens IP position in the field of TCR-based therapeutics
  • 20 August 2018

    Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
  • 16 July 2018

    Immunocore Announces Management Change
  • 4 June 2018

    Immunocore Presents New IMCgp100-102 Data that Show Durable Response and Robust Overall Survival Rate in Patients with Metastatic Uveal Melanoma
  • 22 May 2018

    Immunocore to Present New Data from IMCgp100-102 Trial in Metastatic Uveal Melanoma at 2018 ASCO Annual Meeting
  • 21 May 2018

    Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards
  • 8 February 2018

    Immunocore Announces Leadership Change
  • 4 January 2018

    Immunocore Strengthens its Board with Appointments of Laura Wade-Gery and Kristine Peterson as Non-Executive Directors
  • 11 December 2017

    Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
  • ← Previous
  • 1
  • 2
  • 3
  • 4 (current)
  • 5
  • 6
  • 7
  • …
  • 11
  • Next →

Sign up to receive news email alerts

News archive
  • Show all
  • 2021 (8)
  • 2020 (8)
  • 2019 (13)
  • 2018 (10)
  • 2017 (13)
  • 2016 (11)
  • 2015 (20)
  • 2014 (6)
  • 2013 (11)
  • 2012 (3)
  • 2011 (1)
  • 2010 (4)
  • 2009 (1)
  • 2008 (1)

Immunocore

Immunocore
  • About us
  • Our science
  • Our therapy areas
  • For patients
  • Investors/Media
  • News
  • Careers
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd